Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Overview of the 2010 Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee meeting regarding ticagrelor.

× No keyword cloud information.

9 in total

1. Total cardiovascular events analysis of the EXAMINE trial in patients with type 2 diabetes and recent acute coronary syndrome.

Authors: Matthew A Cavender; William B White; Yuyin Liu; Joseph M Massaro; Richard M Bergenstal; Cyrus R Mehta; Faiez Zannad; Simon Heller; William C Cushman; Christopher P Cannon
Journal: Clin Cardiol Date: 2018-08-16 Impact factor: 2.882

2. [New antiplatelet agents and the question of dual antiplatelet therapy].

Authors: K Schrör
Journal: Internist (Berl) Date: 2012-03 Impact factor: 0.743

Review 3. Prasugrel vs. ticagrelor in acute coronary syndromes: which one to choose?

Authors: Hannes F Alber; Kurt Huber; Otmar Pachinger; Matthias Frick
Journal: Wien Klin Wochenschr Date: 2011-08-03 Impact factor: 1.704

Review 4. Historical perspective and future directions in platelet research.

Authors: B S Coller
Journal: J Thromb Haemost Date: 2011-07 Impact factor: 5.824

Review 5. Antiplatelet therapy in the management of cardiovascular disease in patients with CKD: what is the evidence?

Authors: Nishank Jain; S Susan Hedayati; Ravindra Sarode; Subhash Banerjee; Robert F Reilly
Journal: Clin J Am Soc Nephrol Date: 2012-09-27 Impact factor: 8.237

6. Ticagrelor inhibits the NLRP3 inflammasome to protect against inflammatory disease independent of the P2Y₁₂ signaling pathway.

Authors: Bo Huang; Yufeng Qian; Shujun Xie; Xianhua Ye; Hanwen Chen; Zhifeng Chen; Lihuan Zhang; Jinming Xu; Hu Hu; Shenglin Ma; Paul Héroux; Di Wang; Han-Ming Shen; Yihua Wu; Dajing Xia
Journal: Cell Mol Immunol Date: 2020-06-10 Impact factor: 11.530

Overview of the 2010 Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee meeting regarding ticagrelor.

1. Total cardiovascular events analysis of the EXAMINE trial in patients with type 2 diabetes and recent acute coronary syndrome.

2. [New antiplatelet agents and the question of dual antiplatelet therapy].

Review 3. Prasugrel vs. ticagrelor in acute coronary syndromes: which one to choose?

Review 4. Historical perspective and future directions in platelet research.

Review 5. Antiplatelet therapy in the management of cardiovascular disease in patients with CKD: what is the evidence?

6. Ticagrelor inhibits the NLRP3 inflammasome to protect against inflammatory disease independent of the P2Y₁₂ signaling pathway.

7. Towards personalized medicine based on platelet function testing for stent thrombosis patients.

8. Spontaneous hematoma in the setting of dual anti-platelet therapy with ticagrelor: A case report.

9. Ticagrelor therapy and atrioventricular block: Do we need to worry?

Overview of the 2010 Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee meeting regarding ticagrelor.

1. Total cardiovascular events analysis of the EXAMINE trial in patients with type 2 diabetes and recent acute coronary syndrome.

2. [New antiplatelet agents and the question of dual antiplatelet therapy].

Review 3. Prasugrel vs. ticagrelor in acute coronary syndromes: which one to choose?

Review 4. Historical perspective and future directions in platelet research.

Review 5. Antiplatelet therapy in the management of cardiovascular disease in patients with CKD: what is the evidence?

6. Ticagrelor inhibits the NLRP3 inflammasome to protect against inflammatory disease independent of the P2Y12 signaling pathway.

7. Towards personalized medicine based on platelet function testing for stent thrombosis patients.

8. Spontaneous hematoma in the setting of dual anti-platelet therapy with ticagrelor: A case report.

9. Ticagrelor therapy and atrioventricular block: Do we need to worry?

6. Ticagrelor inhibits the NLRP3 inflammasome to protect against inflammatory disease independent of the P2Y₁₂ signaling pathway.